Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $8.2 million.

  • Revolution Medicines' Other Accumulated Expenses rose 54483.57% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 54483.57%. This contributed to the annual value of $583000.0 for FY2024, which is 8503.59% down from last year.
  • As of Q3 2025, Revolution Medicines' Other Accumulated Expenses stood at $8.2 million, which was up 54483.57% from $462000.0 recorded in Q2 2025.
  • Revolution Medicines' Other Accumulated Expenses' 5-year high stood at $8.2 million during Q3 2025, with a 5-year trough of $99000.0 in Q2 2021.
  • In the last 5 years, Revolution Medicines' Other Accumulated Expenses had a median value of $488000.0 in 2022 and averaged $1.1 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 8563.54% in 2021, then soared by 67148.51% in 2023.
  • Revolution Medicines' Other Accumulated Expenses (Quarter) stood at $311000.0 in 2021, then soared by 62.38% to $505000.0 in 2022, then surged by 671.49% to $3.9 million in 2023, then crashed by 85.04% to $583000.0 in 2024, then surged by 1313.55% to $8.2 million in 2025.
  • Its Other Accumulated Expenses stands at $8.2 million for Q3 2025, versus $462000.0 for Q2 2025 and $651000.0 for Q1 2025.